Mitigation of head and neck cancer service disruption during COVID-19 in Hong Kong through telehealth and multi-institutional collaboration

Alex K F Lee, Ryan H W Cho, Eric H L Lau, Hung K Cheng, Eddy W Y Wong, Peter K M Ku, Jason Y K Chan, Zenon W C Yeung, Alex K F Lee, Ryan H W Cho, Eric H L Lau, Hung K Cheng, Eddy W Y Wong, Peter K M Ku, Jason Y K Chan, Zenon W C Yeung

Abstract

The 2019 novel coronavirus disease (COVID-19) pandemic has been spreading worldwide at an alarming rate. Health-care workers have been confronted with the challenge of not only treating patients with the virus, but also managing the disruption of health-care services caused by COVID-19. In anticipation of outbreak, clinic sessions and operation theater lists have been actively cut back since February 2020 to reduce hospital admissions and clinic attendances. This has severely disrupted health-care services, leading to accumulating clinic caseload and substantial delays for operations. The head and neck cancer service has been faced with the difficult task of managing the balance between infection risk to health-care providers and the risk of disease progression from prolonged waiting times. We share our experience in Hong Kong on the mitigation of head and neck cancer service disruption through telehealth and multi-institution collaboration.

Keywords: COVID-19; Hong Kong; head and neck; otolaryngology; telehealth.

© 2020 Wiley Periodicals, Inc.

Figures

FIGURE 1
FIGURE 1
Workflow for tele‐consultation clinic
FIGURE 2
FIGURE 2
Stratification of head and neck cancer operations [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061‐1069.
    1. Novel Coronavirus Pneumonia Emergency Response Epidemiology T . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145‐151.
    1. Khan S, Nabi G, Han G, et al. Novel coronavirus: how things are in Wuhan. Clin Microbiol Infect. 2020;26:399‐400.
    1. SAR TGoHK. Coronavirus Disease (COVID‐19) in HK. Hong Kong, China: Centre for Health Protection; 2020.
    1. Chan JYK, Wong EWY, Lam W. Practical aspects of otolaryngologic clinical services during the 2019 novel coronavirus epidemic: an experience in Hong Kong. JAMA Otolaryngol Head Neck Surg. 2020. 10.1001/jamaoto.2020.0488.
    1. (HKCORL) THKCoO . The Guide to the Proper Techniques for Gowning and Removal of Personal Protective Equipment (PPE) 2020.
    1. Toronto TCLUo . A Quick Look at the Confidentiality of Zoom Meetings 2020.
    1. Zou L, Ruan F, Huang M, et al. SARS‐CoV‐2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177‐1179.
    1. Vukkadala N, Qian ZJ, Holsinger FC, Patel ZM, Rosenthal E. COVID‐19 and the otolaryngologist—preliminary evidence‐based review. Laryngoscope. 2020. 10.1002/lary.28672.
    1. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 2007;84(1):5‐10.
    1. Jang JY, Choi N, Ko YH, et al. Treatment outcomes in metastatic and localized high‐grade salivary gland cancer: high chance of cure with surgery and post‐operative radiation in T1‐2 N0 high‐grade salivary gland cancer. BMC Cancer. 2018;18(1):672.
    1. Organization WH . Coronavirus disease (COVID‐19) Pandemic.
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239‐1242.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren